- Home
- GSRT vs CERS Comparison
GSRT vs CERS Comparison
Compare GSRT & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSRT
- CERS
- Stock Information
- Founded
- GSRT 2023
- CERS 1991
- Country
- GSRT United States
- CERS United States
- Employees
- GSRT N/A
- CERS N/A
- Industry
- GSRT
- CERS EDP Services
- Sector
- GSRT
- CERS Technology
- Exchange
- GSRT Nasdaq
- CERS Nasdaq
- Market Cap
- GSRT 289.1M
- CERS 347.3M
- IPO Year
- GSRT 2024
- CERS 1997
- Fundamental
- Price
- GSRT $9.94
- CERS $1.86
- Analyst Decision
- GSRT
- CERS Buy
- Analyst Count
- GSRT 0
- CERS 3
- Target Price
- GSRT N/A
- CERS $3.17
- AVG Volume (30 Days)
- GSRT 1.4K
- CERS 1.7M
- Earning Date
- GSRT 01-01-0001
- CERS 03-04-2025
- Dividend Yield
- GSRT N/A
- CERS N/A
- EPS Growth
- GSRT N/A
- CERS N/A
- EPS
- GSRT N/A
- CERS N/A
- Revenue
- GSRT N/A
- CERS $176,229,000.00
- Revenue This Year
- GSRT N/A
- CERS $18.57
- Revenue Next Year
- GSRT N/A
- CERS $10.80
- P/E Ratio
- GSRT N/A
- CERS N/A
- Revenue Growth
- GSRT N/A
- CERS 14.71
- 52 Week Low
- GSRT $9.97
- CERS $1.38
- 52 Week High
- GSRT $10.20
- CERS $2.59
- Technical
- Relative Strength Index (RSI)
- GSRT N/A
- CERS 52.01
- Support Level
- GSRT N/A
- CERS $1.89
- Resistance Level
- GSRT N/A
- CERS $2.24
- Average True Range (ATR)
- GSRT 0.00
- CERS 0.14
- MACD
- GSRT 0.00
- CERS -0.00
- Stochastic Oscillator
- GSRT 0.00
- CERS 24.00
About GSRT GSR III Acquisition Corp. Ordinary Shares
GSR III Acquisition Corp is a blank check company.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.